1 Min Read
* BIOHAVEN COMPLETES ENROLLMENT IN SECOND PIVOTAL PHASE 3 CLINICAL TRIAL OF ORAL CGRP-RECEPTOR ANTAGONIST RIMEGEPANT Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.